

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

Robert M. LORENCE et al

Serial No. 08/260,536

Filed: June 16, 1994



Atty. Ref.: 2370-11

TC/A.U.: 1648

Examiner: Le, Emily M.

For: METHODS FOR TREATING AND DETECTING CANCER USING VIRUSES

\* \* \* \* \*

July 5, 2005

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449.

This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

Pursuant to Rule 37 C.F.R. §1.97(c), a fee of \$180.00 as specified in Rule 17(p) is attached. If there is any shortage in the fee, please charge the deposit account of Nixon & Vanderhye, Account No. 14-1140.

Respectfully submitted,


**NIXON & VANDERHYE P.C.**

07/06/2005 SDENBOB1 00000082 08260536

03 FC:1806

180.00 0P

By:

  
Leonard C. Mitchard  
Reg. No. 29,009

LCM:lfm

901 North Glebe Road, 11th Floor


Arlington, VA 22203-1808

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE  
CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.

2370-11

APPLICANT

Robert M. LORENCE et al

FILING DATE

June 16, 1994

SERIAL NO.

08/260,536

TC/A.U.

1648

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
----------	------	---------	-------	----------	-----------------------

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Clercq, E.D., et al; "Current Concepts of Interferon and Interferon Induction"; <i>Division of Infectious Diseases, Dept. of Medicine, Stanford University School of Medicine, Stanford, California</i> ; pp. 17-46 (1970).
	Hilleman, M.R.; "Interferon Induction and Utilization"; <i>J. Cell Physiol.</i> ; Vol. 71 pp. 43-60 (1968).
	Eaton, M.D., et al; "Contribution of Antiviral Immunity to Oncolysis by Newcastle Disease Virus in a Murine Lymphoma"; <i>Journal of the National Cancer Institute</i> ; Vol. 39, No. 1-6 pp. 1089-1097 (1967).
	Dalglish, A.G., et al; "The Development of Therapeutic Vaccines for the Management of Malignant Melanoma"; <i>Cancer Surveys</i> , Vol. 26; pp. 289-319 (1996).
	Japanese Patent Office; Public Patent Disclosure Bulletin No. S51-73117; Bulletin Date June 24, 1976; Patent Application No. S49-147261; Patent Application Date; December 19, 1974, (6 pgs).
	Nature New Biology; Vol. 245, No. 147, October 24, 1973, "Role of Interferon in the Anti-Melanoma Effects of Poly (I), Poly (C) and Newcastle Disease Virus; pp 229-230.
	Baars, A., et al; "Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients"; <i>Annals of Oncology</i> ; Vol. 11, pp. 965-970 (2000).
	Schirmacher, V.; "In situ analysis of tumor-specific CTL effector and memory responses elicited by tumor vaccination"; <i>International Journal of Oncology</i> ; Vol. 15; pp. 27-227 (1999).
	Vile, R.G.; "Vironology-not yet, but soon?"; <i>Nature Biotechnology</i> , Nature Publishing Group; Vol. 19 pp. 1020-1022, (2001).
	Yotnda, P., et al; "Targeted delivery of adenoviral vectors by cytotoxic T cells"; <i>Blood</i> ; Vol. 104, No. 8, pp 2272-2280 (2004).
	Harrington, K., et al; "Cells as Vehicles for Cancer Gene Therapy: The Missing Link Between Targeted Vectors and Systemic Delivery"; <i>Human Gene Therapy</i> ; Vol. 13; pp. 1263-1280 (2002).
	Crystal, R.G., et al; "Analysis of Risk Factors for Local Delivery of Low- and Intermediate-Dose Adenovirus Gene Transfer Vectors to Individuals with a Spectrum of Comorbid Conditions"; <i>Human Gene Therapy</i> ; Vol. 13; pp. 65-100 (2002).
	Chen, Y., et al; "Pre-Existent Adenovirus Antibody Inhibits Systemic Toxicity and Antitumor Activity of CN706 in the Nude Mouse LNCaP Xenograft Model: Implications and Proposals for Human Therapy"; <i>Human Gene Therapy</i> ; Vol. 11; pp. 1553-1567 (2000).
	Jia, W., et al; "Viral Vectors for Cancer Gene Therapy: Viral Dissemination and Tumor Targeting"; <i>Current Gene Therapy</i> ; Vol. 5, pp. 133-142 (2005).
	Morrissey, R.E., et al; "Rodent Nonclinical Safety Evaluation Studies of SCH 58500, an Adenoviral Vector for the p53 Gene"; <i>Toxicological Sciences</i> ; Vol. 65, pp. 266-275 (2002).
	Plager, C., et al; "Adjuvant Immunotherapy of M.D. Anderson Hospital (MDAH Stage III-B Malignant Melanoma with Newcastle Disease Virus Oncolysate"; <i>Proceedings of American Society of Clinical Oncology</i> ; Vol. 9 p 281; #1091 (March 1990)
	Leibrich, W., et al; "In vitro and Clinical Characterisation of a Newcastle Disease Virus-modified Autologous Tumour Cell Vaccine for Treatment of Colorectal Cancer Patients"; <i>Eur J. Cancer</i> ; Vol. 27, No. 6, pp (703-710 (1991).

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

2370-11

08/260,536

APPLICANT

Robert M. LORENCE et al

(Use several sheets if necessary)

FILING DATE

TC/A.U.

June 16, 1994

1648

Mallmann, P.; "Autologous Tumor-Cell Vaccination and Lymphokine-Activated Tumor-Infiltrating Lymphocytes (LAK-TIL); *Hybridoma*; Vol. 12, No. 5, pp 559-566 (1993).

Murray, D.R., et al; "Viral Oncolysate in the Management of Malignant Melanoma II. Clinical Studies"; *Cancer*; Vol. 46, No. 2; pp680-686 (1977).

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.